Pacifico Biolabs, a German mycelium fermentation company, is revolutionizing protein production by utilizing existing brewery infrastructure to scale production and lower costs. By fermenting mycelium in brewery tanks, the company has significantly reduced capital expenditure compared to purpose-built facilities, leading to a unique cost structure that enables competitive pricing with conventional meat products. With the ability to leverage idle European brewery capacity, Pacifico Biolabs could potentially produce enough mycelium to replace all European chicken consumption, showcasing the vast opportunity presented by existing fermentation infrastructure.

Driven by the goal of achieving cost parity with conventional meat, Pacifico Biolabs has already reached parity for chicken breast production and is working towards further reducing costs. The company believes that as production volume increases, costs will continue to decrease, positioning them to surpass meat benchmarks in terms of affordability. By focusing on scalability, operational efficiency, and optimization of fermentation processes, Pacifico Biolabs is poised to disrupt the protein industry and offer consumers a sustainable, cost-effective alternative to meat.